| Mar'19 | Mar'18 | Mar'17 | Mar'16 | |||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net Income (Loss) Attributable to Parent | ||||||
-129,065 | -221,573 | -180,951 | -133,145 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
In-process research and development expenses | ||||||
- | - | 0 | 5,252 | |||
Loss on disposal of fixed assets | ||||||
-148 | -24 | 0 | 0 | |||
Unrealized foreign currency translation adjustment | ||||||
-785 | 252 | -378 | 0 | |||
Share-based compensation expense | ||||||
16,429 | 31,878 | 36,370 | 72,386 | |||
Depreciation and non-cash amortization | ||||||
2,450 | 3,083 | 249 | 14 | |||
Noncash gain on long-term investment | ||||||
5,871 | 0 | - | - | |||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
3,685 | -4,283 | 1,592 | 4,860 | |||
Deferred tax assets | ||||||
0 | -2,709 | 2,386 | 323 | |||
Income tax receivable | ||||||
-25 | 1,093 | -312 | 1,155 | |||
Other non-current assets | ||||||
973 | 0 | - | - | |||
Accounts payable | ||||||
-2,251 | -4,602 | 7,929 | 219 | |||
Due to Roivant Sciences Ltd. and certain of its wholly owned subsidiaries | ||||||
-956 | -1,871 | 1,105 | -311 | |||
Accrued expenses | ||||||
-11,243 | -2,934 | 26,477 | 8,391 | |||
Operating lease liabilities | ||||||
- | - | 0 | 185 | |||
Net cash used in operating activities | ||||||
-134,207 | -190,348 | -112,109 | -53,347 | |||
Cash flows from investing activities: | ||||||
Purchase of in-process research and development | ||||||
- | - | 0 | 5,252 | |||
Purchases of property and equipment | ||||||
202 | 4,284 | 105 | 94 | |||
Net cash used in investing activities | ||||||
-202 | -4,284 | -105 | -5,346 | |||
Cash flows from financing activities: | ||||||
Payments on long-term debt | ||||||
9,707 | 0 | - | - | |||
Cash proceeds from issuance of common shares in initial public offering, net of underwriting discount | ||||||
- | - | 0 | 336,893 | |||
Initial public offering costs paid | ||||||
- | - | 0 | 2,351 | |||
Capital contribution received from Roivant Sciences, Inc. | ||||||
1,894 | 324 | 0 | 751 | |||
Repayment of amounts due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company | ||||||
- | - | 0 | 627 | |||
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc. for amounts paid on behalf of the Company | ||||||
- | - | 0 | 278 | |||
Payment of contingent liability | ||||||
- | - | 5,000 | 0 | |||
Cash proceeds from stock option exercises | ||||||
335 | 1,557 | 36 | 0 | |||
Cash proceeds from debt financing, net of financing costs | ||||||
- | - | 53,500 | - | |||
Cash proceeds from issuance of common shares, net of costs | ||||||
94,549 | 134,515 | 0 | - | |||
Net cash provided by financing activities | ||||||
87,071 | 136,396 | 48,536 | 334,944 | |||
Net change in cash and cash equivalents | ||||||
-47,338 | -58,236 | - | - | |||
Net change in cash and cash equivalents | ||||||
- | - | -63,678 | 276,251 | |||
Recognition of warrant issued in debt financing | ||||||
- | - | 2,261 | 0 | |||
Non-cash operating activities: | ||||||
Issuance of common stock upon exercise of warrant | ||||||
0 | 2,594 | 0 | - | |||
Income taxes | ||||||
71 | 377 | 1,014 | 1,279 | |||
Interest | ||||||
6,376 | 6,365 | 435 | 0 | |||